Influence of the high-affinity growth hormone (GH)-binding protein on plasma profiles of free and bound GH and on the apparent half-life of GH. Modeling analysis and clinical applications
- PMID: 8432866
- PMCID: PMC287997
- DOI: 10.1172/JCI116243
Influence of the high-affinity growth hormone (GH)-binding protein on plasma profiles of free and bound GH and on the apparent half-life of GH. Modeling analysis and clinical applications
Erratum in
- J Clin Invest 1993 Aug;92(2):following 1108
- J Clin Invest 1993 May;91(5):following 2334
Abstract
The discovery of a specific high-affinity growth hormone (GH) binding protein (GH-BP) in plasma adds complexity to the dynamics of GH secretion and clearance. Intuitive predictions are that such a protein would damp sharp oscillations in GH concentrations otherwise caused by bursts of GH secretion into the blood volume, prolong the apparent half-life of circulating GH, and contribute a reservoir function. To test these implicit considerations, we formulated an explicit mathematical model of pulsatile GH secretion and clearance in the presence of absence of a specific high-affinity GH-BP. Simulation experiments revealed that the pulsatile mode of physiological GH secretion creates a highly dynamic (nonequilibrium) system, in which the half-life of free GH, its instantaneous secretion rate, and the GH-BP affinity and capacity all contribute to defining momentary levels of free, bound, and total GH, the percentage of GH bound to protein, and the percentage occupancy of GH-BP [corrected]. In contrast, the amount of free GH at equilibrium is specified only by the GH distribution volume and secretion rate and the half-life of free hormone. We conclude that the in vivo dynamics of GH secretion, trapping, and clearance from the circulation offer a variety of regulatory loci at which the time structure of free, bound, and total GH delivery to target tissues can be controlled physiologically.
Similar articles
-
Dual defects in pulsatile growth hormone secretion and clearance subserve the hyposomatotropism of obesity in man.J Clin Endocrinol Metab. 1991 Jan;72(1):51-9. doi: 10.1210/jcem-72-1-51. J Clin Endocrinol Metab. 1991. PMID: 1986027
-
Properties of spontaneous growth hormone secretory bursts and half-life of endogenous growth hormone in boys with idiopathic short stature. Genentech Collaborative Group.J Clin Endocrinol Metab. 1992 Apr;74(4):766-73. doi: 10.1210/jcem.74.4.1548338. J Clin Endocrinol Metab. 1992. PMID: 1548338
-
Differential impact of age, sex steroid hormones, and obesity on basal versus pulsatile growth hormone secretion in men as assessed in an ultrasensitive chemiluminescence assay.J Clin Endocrinol Metab. 1995 Nov;80(11):3209-22. doi: 10.1210/jcem.80.11.7593428. J Clin Endocrinol Metab. 1995. PMID: 7593428 Clinical Trial.
-
Contemporary tools for the analysis of episodic growth hormone secretion and clearance in vivo.Acta Paediatr Scand Suppl. 1988;347:63-82. Acta Paediatr Scand Suppl. 1988. PMID: 3075841 Review.
-
Secretion of prolactin and growth hormone in relation to ovarian activity in the dog.Reprod Domest Anim. 2001 Aug;36(3-4):115-9. Reprod Domest Anim. 2001. PMID: 11555356 Review.
Cited by
-
In vitro bioassay as a predictor of in vivo response.Theor Biol Med Model. 2005 Feb 7;2:3. doi: 10.1186/1742-4682-2-3. Theor Biol Med Model. 2005. PMID: 15698478 Free PMC article.
-
Growth hormone binding protein and free growth hormone in chronic renal failure.Pediatr Nephrol. 1996 Jun;10(3):328-30. doi: 10.1007/BF00866772. Pediatr Nephrol. 1996. PMID: 8792398 Review.
-
Sex-steroid modulation of growth hormone (GH) secretory control: three-peptide ensemble regulation under dual feedback restraint by GH and IGF-I.Endocrine. 2003 Oct;22(1):25-40. doi: 10.1385/ENDO:22:1:25. Endocrine. 2003. PMID: 14610296 Review.
-
Human GH pulsatility: an ensemble property regulated by age and gender.J Endocrinol Invest. 2003 Sep;26(9):799-813. doi: 10.1007/BF03345229. J Endocrinol Invest. 2003. PMID: 14964431 Review.
-
Circulating growth hormone binding proteins.J Endocrinol Invest. 1994 Jan;17(1):67-81. doi: 10.1007/BF03344965. J Endocrinol Invest. 1994. PMID: 8006328 Review. No abstract available.